US-listed company LIXTE Biotechnology launches crypto reserve strategy, plans to allocate 25% of funds to BTC
According to ChainCatcher, Nasdaq-listed company LIXTE Biotechnology has announced that its board of directors has approved a strategic capital allocation plan to acquire cryptocurrencies as part of the company’s funds. The board has also approved allocating 25% of its funds to cryptocurrencies, including Bitcoin and potentially other digital assets as appropriate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The total on-chain holdings of US spot Bitcoin ETFs have surpassed 1.32 million BTC.
Yesterday, the net inflow of US spot Ethereum ETFs was $76.6 million.
Analyst: Bitcoin has bottomed out in the short term, a rebound towards $100,000 may occur
BlackRock IBIT holdings drop to 777,700 BTC
Trending news
MoreCrypto prices
More
